First Week of TARS February 2026 Options Trading

Tarsus Pharmaceuticals (TARS) is presented as an options-income opportunity at a current stock price of $81.36. Selling the $75 put (bid $2.20) would set an effective purchase basis of $72.80 and is out‑of‑the‑money by ~8% with a 68% chance to expire worthless, equating to a 2.93% yield (17.84% annualized). Conversely, selling the $85 covered call (bid $4.00) against shares bought at $81.36 offers a 9.39% total return to the February 2026 expiration, with a 54% chance to expire worthless and a 4.92% premium boost (29.91% annualized). Implied volatilities are 53% on the put, 49% on the call, versus a trailing 12‑month volatility of 48%, framing these trades as income-oriented strategies with defined upside/cost tradeoffs.

Analysis

Market structure: The option market is currently rewarding sellers — implied vol (put 53%, call 49%) exceeds realized TTM vol (48%), creating a persistent options risk premium that benefits income strategies. Sellers of the $75 Feb‑2026 put (bid $2.20; 68% chance to expire worthless) and $85 covered call (bid $4.00; 54% chance to expire worthless) directly capture yields of ~2.9% and ~4.9% over ~1 year equivalents (17.8% and 29.9% annualized). Brokers and liquidity providers also win from increased derivatives flow; long-biotech speculators who rely on upside capture are the marginal losers if selling pressure persists.

Risk assessment: Tail risks are classic biotech binaries — adverse clinical/ FDA outcomes or dilution could send TARS below $60 (40%+ gap) rapidly, invalidating short-put/call-write theses. Immediate (days) risk is IV spikes around news; short/covered option delta exposure becomes dangerous inside 30–90 days of catalysts; medium term (3–12 months) runway and funding announcements matter; long term depends on product approvals and commercialization. Hidden dependency: sector-wide volatility (XBI/IBB) correlations can reprice TARS IV by +10–30 vol points in a risk-off biotech selloff.

Trade implications: Direct actionable plays: (A) sell-to-open Feb‑2026 $75 put to acquire TARS at $72.80 effective if comfortable owning shares; position size <=1–2% NAV and buy-to-close if stock < $65 or IV > 80%. (B) Buy 100 TARS and sell Feb‑2026 $85 covered call to capture ~9.4% gross to call (basis ~$77.36), cap upside but generate ~5% yield; use a hard stop at -15% from entry. For volatility plays, consider long-dated call backspreads or calendar spreads if anticipating a positive binary within 90–180 days; avoid naked short straddles.

Contrarian angles: The market underestimates asymmetric loss from binary negative outcomes — sellers are paid modest premiums vs potential 30–50% downside; this implies option-selling returns are compensation for tail risk rather than free alpha. Conversely, if no binary materializes, current sellers earn elevated annualized yields (20–30%) versus cash; historical parallels (small-cap biotech with stable preclinical windows) show covered-call strategies outperform buy-and-hold over 6–12 months but lag in breakout scenarios. Unintended consequence: repeated assignment creates concentrated equity exposure and forces financing/dilution risk if company capital raises occur while holders are assigned.

Key Decisions for Investors

• Sell-to-open 1 Feb‑2026 TARS $75 put (collect ~$2.20) size 0.5–1.0% NAV to target effective entry $72.80; set buy-to-close if TARS < $65 or IV > 80% or on negative clinical/FDA headlines within 90 days.
• Establish covered-call: buy 100 TARS at market and sell Feb‑2026 $85 call (collect ~$4.00) for net basis ≈ $77.36; target hold 6–12 months, take profit if stock > $95 or close position if stock < $65 (protect downside).
• If anticipating a near-term positive catalyst within 60–180 days, buy a directional call spread (e.g., long Mar‑2026 $80 call / short Mar‑2026 $95 call) to limit cost while retaining ~2x upside exposure; allocate max 0.5% NAV.
• Pair trade for idiosyncratic exposure: long TARS (equal dollar) / short XBI (or IBB) sized to net delta ≈ 0 to isolate company-specific upside; hold 3–6 months and rebalance if sector IV diverges >10 vol points.